GI
AXSM icon

GAMMA Investing’s Axsome Therapeutics AXSM Stock Holding History

GAMMA Investing’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.9K Buy
347
+45
+15% +$9.76K ﹤0.01% 1926
2026
Q1 		$51K Buy
302
+34
+13% +$5.87K ﹤0.01% 2162
2025
Q4 		$48.9K Buy
268
+106
+65% +$14.8K ﹤0.01% 2090
2025
Q3 		$19.7K Buy
162
+98
+153% +$11K ﹤0.01% 2523
2025
Q2 		$6.68K Sell
64
-125
-66% -$13.2K ﹤0.01% 3000
2025
Q1 		$22K Buy
189
+132
+232% +$15K ﹤0.01% 2331
2024
Q4 		$4.82K Sell
57
-22
-28% -$2.02K ﹤0.01% 2930
2024
Q3 		$7.1K Buy
79
+42
+114% +$3.67K ﹤0.01% 2597
2024
Q2 		$2.98K Buy
37
+17
+85% +$1.26K ﹤0.01% 2752
2024
Q1 		$1.6K Sell
20
-1
-5% -$84 ﹤0.01% 2815
2023
Q4 		$1.89K Buy
+21
New +$1.4K ﹤0.01% 2593

Other funds holding AXSM

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return
CA
Cannon Advisors Charlotte, North Carolina $164M AUM 30.34% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

GAMMA Investing's AXSM Position: Q2 2026 in Review

GAMMA Investing increased its Axsome Therapeutics (AXSM) stake by 15% in Q2 2026, buying an estimated $9.76K and bringing the position to 347 shares worth $84.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1926.

GAMMA Investing first reported a position in AXSM in Q4 2023 and has held it in 11 quarters since. 38 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • GAMMA Investing held 347 shares of Axsome Therapeutics worth $84.9K as of Q2 2026.
  • GAMMA Investing bought 45 Axsome Therapeutics shares in Q2 2026, an estimated $9.76K.
  • Axsome Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #1926 holding.
  • GAMMA Investing first reported a position in Axsome Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 38 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.